Back to the Basics of Dyslipidemia

Background

Background (cont)

Pathophysiology of the Coronary Artery Athero-Inflammatory-Thrombotic Process

Potential Beneficial Effects of EPA on Clinical CV Endpoints

Cellular and Molecular Mechanisms of Atherosclerosis

Integrated Perspective on CV Risk Factors and Atherosclerosis

LDL Oxidation Leads to Plaque Instability and Reduced Rates of Clearance

Proposed Mechanisms for the Atherogenicity of TG-Rich Lipoproteins

Effects of Omega-3 (EPA) Fatty Acids on Membranes

Comparative Effects of EPA, Fenofibrate, Niacin, Gemfibrozil, and Vitamin E on Human Small Dense LDL Oxidation

EPA Inhibits Human sdLDL Oxidation In Vitro as Compared to DHA Over Time

Effects of EPA vs Other TG-lowering Agents

Treatment Considerations

Statins

Combined Effects of EPA and Atorvastatin on Human Endothelial Function after Treatment With Oxidized LDL

Factors Contributing to Cardiometabolic Risk

Role of Insulin Resistance and Compensatory Hyperinsulinemia

Metabolic Syndrome What Can We Do About It?

Treatment Options for Metabolic Syndrome

EPA + DHA and Lipid Levels in Patients With TG > 500 mg/dL

The MARINE Study

ANCHOR Study: EPA + Statin vs Statin Alone EPA and Lipid Endpoints

Potential Beneficial Effects of EPA on Clinical CV Endpoints

Advantages of EPA Compared With DHA

Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

JELIS EPA Reduced Major Coronary Events JELIS EPA Reduced Major Coronary Events* in Hypercholesterolemic Patients on Statins

JELIS

EPA Effects

Biologic Plausibility, Vascular/Endothelial Function Effects, and Clinical Outcomes Associated With Commonly Used TG-Lowering Medications

GISSI vs JELIS (Omega-3 Outcomes Studies)

Prescription EPA-Only vs Omega-3 Dietary Supplements

Prescription EPA-Only vs Omega-3 Dietary Supplements (cont)

REDUCE-IT Reduction of Cardiovascular Events With EPA -- Intervention Trial

Abbreviations

Abbreviations (cont)

Abbreviations (cont)